SuperworthAvantor AVTR
- Market cap
- $11.7B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.8×
- EV/EBIT
- 30.5×
- Revenue, 12 months
- $6.6B
- −2% on a year ago
- Net margin
- −8.8%
- Free cash flow yield
- 3.9%
Avantor trades at 1.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $6.6B over the last twelve months, down 2% on a year earlier with a −9% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.7B−7% | $1.7B−4% | $1.7B−6% | $1.7B−2% | $1.7B−0% | $1.7B−2% | $1.6B−6% | $1.7B−1% | $1.6B−5% | $1.7B−1% | $1.6B+0% | $1.7B+1% | |
| Cost of revenue | $1.1B−5% | $1.2B−2% | $1.1B−4% | $1.1B−3% | $1.1B+1% | $1.1B−3% | $1B−6% | $1.1B+1% | $1.1B−5% | $1.1B+1% | $1.1B+3% | $1.2B+2% |
| Gross profit | $578.6M−11% | $570.4M−7% | $570.5M−9% | $581.5M−1% | $564.4M−3% | $562.9M−1% | $534.9M−6% | $554.1M−5% | $526.5M−7% | $523.9M−7% | $500.7M−6% | $537M−3% |
| SG&A | $368.4M−2% | $387.1M+7% | $424.2M+8% | $405.7M+14% | $439.8M+19% | $371.4M−4% | $387.5M−9% | $425.3M+5% | $390.3M−11% | $392.4M+6% | $401.2M+4% | $415.2M−2% |
| $210.2M−24% | $183.3M−27% | $146.3M−37% | $175.8M+145% | $124.6M−41% | $638.1M+248% | $147.4M+1% | $128.8M−27% | −$648.8M | $126.4M−80% | $99.5M−33% | $121.8M−5% | |
| Interest expense | $72.4M+8% | $65.3M−6% | $64.3M−13% | $60.9M−17% | $48.7M−33% | $44.9M−31% | $42.2M−34% | $43.4M−29% | $44.2M−9% | $40M−11% | $42.9M+2% | $39.4M−9% |
| Pre-tax income | $136.5M−35% | $119.5M−32% | $80.6M−48% | $114.6M | $74.5M−45% | $584.2M+389% | $85.7M+6% | $81.7M−29% | −$689.5M | $80.8M−86% | $55.5M−35% | $81.2M−1% |
| $28.1M−32% | $21M−36% | $20.2M−41% | $21.7M+262% | $16.7M−41% | $83.8M+299% | $21.2M+5% | $17M−22% | $22.3M+34% | $28.4M−66% | $12.2M−43% | $43.1M+154% | |
| Net income | $108.4M−35% | $98.5M−31% | $60.4M−50% | $92.9M | $57.8M−47% | $500.4M+408% | $64.5M+7% | $64.7M−30% | −$711.8M | $52.4M−90% | $43.3M−33% | $38.1M−41% |
| $0.16−36% | $0.15−29% | $0.09−50% | $0.14 | $0.08−50% | $0.73+387% | $0.09+0% | $0.09−36% | −$1.04 | $0.08−89% | $0.06−33% | $0.06−33% | |
| 678.5M−0% | 679.3M+0% | 681.4M+1% | 682.6M+1% | 683M+1% | 681.3M+0% | 682.4M+0% | 681.8M−0% | 681.7M−0% | 678.2M−1% | 676.8M−1% | 677.2M−1% |
Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Income tax: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 9 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. Q4 FY18: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 7 periods, Q4 FY19 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Avantor's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AVTRAvantor | $11.7B | n/m | 42.1× | n/m | 1.8× | −2% | −8.8% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | n/m | 9.1× | +85% | 10.6% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | n/m | 4.2× | +2% | 17.7% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| BLLNBillionToOne | $5.1B | 166× | 151× | n/m | 12.8× | +90% | 9.5% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | n/m | 6.9× | +17% | 20.4% |
| Peer median | $13.8B | 38.4× | 34.7× | 25.6× | 6.4× | +8% | 10.1% |
More on Avantor
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .